Phreesia (NYSE:PHR) Price Target Increased to $28.00 by Analysts at Citigroup

Phreesia (NYSE:PHRGet Rating) had its price target raised by equities research analysts at Citigroup from $25.00 to $28.00 in a research note issued on Friday, The Fly reports. Citigroup’s price objective indicates a potential upside of 4.83% from the stock’s current price.

Other equities analysts have also recently issued reports about the company. Canaccord Genuity Group lowered their price target on Phreesia from $37.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, September 8th. KeyCorp started coverage on shares of Phreesia in a research note on Thursday, September 15th. They set an “overweight” rating and a $40.00 target price for the company. DA Davidson began coverage on shares of Phreesia in a research note on Wednesday, October 12th. They issued a “neutral” rating and a $25.00 price target on the stock. They noted that the move was a valuation call. Royal Bank of Canada upped their price objective on shares of Phreesia from $20.00 to $22.00 and gave the stock a “sector perform” rating in a report on Thursday, September 8th. Finally, SVB Leerink lifted their target price on shares of Phreesia from $27.00 to $31.00 and gave the company a “market perform” rating in a report on Thursday, September 8th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.21.

Phreesia Stock Up 2.5 %

Shares of NYSE PHR opened at $26.71 on Friday. The company has a market capitalization of $1.40 billion, a P/E ratio of -7.65 and a beta of 0.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.40 and a quick ratio of 4.40. The company has a 50 day simple moving average of $25.21 and a 200-day simple moving average of $24.12. Phreesia has a 1 year low of $13.19 and a 1 year high of $49.86.

Phreesia (NYSE:PHRGet Rating) last issued its quarterly earnings data on Wednesday, September 7th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.10. Phreesia had a negative return on equity of 45.05% and a negative net margin of 73.73%. The company had revenue of $67.87 million during the quarter, compared to analyst estimates of $65.87 million. On average, equities research analysts predict that Phreesia will post -3.62 earnings per share for the current year.

Insider Activity

In related news, SVP Michael J. Davidoff sold 1,075 shares of the business’s stock in a transaction on Tuesday, October 18th. The stock was sold at an average price of $25.26, for a total transaction of $27,154.50. Following the completion of the transaction, the senior vice president now directly owns 106,114 shares of the company’s stock, valued at approximately $2,680,439.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Michael J. Davidoff sold 1,075 shares of Phreesia stock in a transaction dated Tuesday, October 18th. The stock was sold at an average price of $25.26, for a total value of $27,154.50. Following the completion of the transaction, the senior vice president now owns 106,114 shares in the company, valued at approximately $2,680,439.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Allison C. Hoffman sold 1,290 shares of the business’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $28.58, for a total value of $36,868.20. Following the transaction, the general counsel now directly owns 107,300 shares of the company’s stock, valued at $3,066,634. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,002 shares of company stock worth $618,711. Corporate insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Phreesia

Large investors have recently modified their holdings of the company. Bank of New York Mellon Corp grew its stake in shares of Phreesia by 12.9% during the third quarter. Bank of New York Mellon Corp now owns 198,639 shares of the company’s stock worth $5,061,000 after purchasing an additional 22,736 shares in the last quarter. Capital Impact Advisors LLC raised its stake in Phreesia by 10.3% in the third quarter. Capital Impact Advisors LLC now owns 20,411 shares of the company’s stock valued at $488,000 after buying an additional 1,904 shares in the last quarter. FourThought Financial LLC lifted its holdings in Phreesia by 16.4% during the 3rd quarter. FourThought Financial LLC now owns 3,081 shares of the company’s stock worth $79,000 after buying an additional 434 shares during the last quarter. Fred Alger Management LLC acquired a new position in shares of Phreesia during the 3rd quarter worth about $2,028,000. Finally, Tamarack Advisers LP increased its holdings in shares of Phreesia by 6.1% in the 3rd quarter. Tamarack Advisers LP now owns 260,000 shares of the company’s stock valued at $6,625,000 after acquiring an additional 15,000 shares during the last quarter. 89.39% of the stock is owned by hedge funds and other institutional investors.

Phreesia Company Profile

(Get Rating)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments.

Further Reading

The Fly logo

Analyst Recommendations for Phreesia (NYSE:PHR)

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.